Salarius Pharmaceuticals, Inc.
SLRX
Price:
$1.49
Market Cap:
$2.15M
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea;...[Read more]
Industry
Biotechnology
IPO Date
2015-01-29
Stock Exchange
NASDAQ
Ticker
SLRX
The ROE as of September 2024 (TTM) for Salarius Pharmaceuticals, Inc. (SLRX) is -148.64%
According to Salarius Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -148.64%. This represents a change of 262.98% compared to the average of -40.95% of the last 4 quarters.
Salarius Pharmaceuticals, Inc. (SLRX) Historical ROE (quarterly & annually)
How has SLRX ROE performed in the past?
The mean historical ROE of Salarius Pharmaceuticals, Inc. over the last ten years is -110.98%. The current -148.64% ROE has changed 33.93% with respect to the historical average. Over the past ten years (40 quarters), SLRX's ROE was at its highest in in the December 2014 quarter at 57.23%. The ROE was at its lowest in in the March 2023 quarter at -94.64%.
Average
-110.98%
Median
-59.80%
Minimum
-302.13%
Maximum
0%
Salarius Pharmaceuticals, Inc. (SLRX) ROE by Quarter and Year
Discovering the peaks and valleys of Salarius Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 820.89%
Maximum Annual ROE = 0%
Minimum Annual Increase = -Infinity%
Minimum Annual ROE = -302.13%
| Year | ROE | Change |
|---|---|---|
| 2023 | -237.22% | -21.48% |
| 2022 | -302.13% | 820.89% |
| 2021 | -32.81% | 2.44% |
| 2020 | -32.03% | -39.59% |
| 2019 | -53.01% | -77.55% |
| 2018 | -236.15% | 99.61% |
| 2017 | -118.31% | 77.69% |
| 2016 | -66.58% | 110.63% |
| 2015 | -31.61% | -Infinity% |
Salarius Pharmaceuticals, Inc. (SLRX) Average ROE
How has SLRX ROE performed in the past?
The current ROE of Salarius Pharmaceuticals, Inc. (SLRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-190.72%
5-year avg
-131.44%
10-year avg
-110.98%
Salarius Pharmaceuticals, Inc. (SLRX) ROE vs. Peers
How is SLRX’s ROE compared to its peers?
Salarius Pharmaceuticals, Inc.’s ROE is less than Akari Therapeutics, Plc (1.04%), greater than Axcella Health Inc. (-3582.11%), greater than Magenta Therapeutics, Inc. (-61.71%), greater than Histogen Inc. (-108.33%), greater than Timber Pharmaceuticals, Inc. (-520.78%), greater than Artelo Biosciences, Inc. (-37.69%), greater than Nutriband Inc. (-76.31%), greater than Aileron Therapeutics, Inc. (-47.94%), greater than First Wave BioPharma, Inc. (-28.76%), greater than SAB Biotherapeutics, Inc. (-94.04%), less than Vaccinex, Inc. (1.11%), greater than GeoVax Labs, Inc. (-852.58%), greater than Corvus Pharmaceuticals, Inc. (-53.99%), greater than Mereo BioPharma Group plc (-63.39%), greater than Affimed N.V. (-155.57%), greater than Pieris Pharmaceuticals, Inc. (-97.28%), greater than Artelo Biosciences, Inc. (-37.69%), greater than Fresh Tracks Therapeutics, Inc. (-58.16%),
| Company | ROE | Market cap |
|---|---|---|
| 1.04% | $35.02M | |
| -3582.11% | $0 | |
| -61.71% | $42.44M | |
| -108.33% | $939.79K | |
| -520.78% | $1.18M | |
| -37.69% | $13.07K | |
| -76.31% | $49.16M | |
| -47.94% | $60.66M | |
| -28.76% | $5.99M | |
| -94.04% | $26.21M | |
| 1.11% | $9.73M | |
| -852.58% | $28.68M | |
| -53.99% | $252.08M | |
| -63.39% | $664.26M | |
| -155.57% | $57.26M | |
| -97.28% | $22.50M | |
| -37.69% | $3.87M | |
| -58.16% | $4.42M |
Build a custom stock screener for Salarius Pharmaceuticals, Inc. (SLRX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Salarius Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Salarius Pharmaceuticals, Inc. (SLRX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Salarius Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Salarius Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Salarius Pharmaceuticals, Inc. (SLRX)?
What is the highest ROE for Salarius Pharmaceuticals, Inc. (SLRX)?
What is the 3-year average ROE for Salarius Pharmaceuticals, Inc. (SLRX)?
What is the 5-year average ROE for Salarius Pharmaceuticals, Inc. (SLRX)?
How does the current ROE for Salarius Pharmaceuticals, Inc. (SLRX) compare to its historical average?